Edition:
United Kingdom

Zhejiang Huahai Pharmaceutical Co Ltd (600521.SS)

600521.SS on Shanghai Stock Exchange

13.29CNY
13 Nov 2018
Change (% chg)

¥-0.23 (-1.70%)
Prev Close
¥13.52
Open
¥13.39
Day's High
¥13.44
Day's Low
¥12.75
Volume
39,146,776
Avg. Vol
16,203,647
52-wk High
¥32.83
52-wk Low
¥10.62

Chart for

About

ZHEJIANGHUAHAIPHARMACEUTICALCO., LTD is a China-based company, principally engaged in the manufacture and distribution of active pharmaceutical ingredients (APIs), intermediates and preparations. The Company's main products are classified as -pril series, -sartan series and preparations, including irbesartan tablets, paroxetine... (more)

Overall

Beta: 0.69
Market Cap(Mil.): ¥16,911.34
Shares Outstanding(Mil.): 1,250.84
Dividend: 0.17
Yield (%): 1.23

Financials

  600521.SS Industry Sector
P/E (TTM): 41.32 28.00 29.57
EPS (TTM): 0.33 -- --
ROI: 7.25 13.26 12.77
ROE: 8.46 15.04 14.47

BRIEF-Zhejiang Huahai Pharmaceutical Clarifies Reports Related To Sandoz's Product Recall

* SAYS IT CLARIFIES ONLINE REPORTS ON HUAHAI BEING INVOLVED IN MANUFACTURING RAW MATERIALS CONTAINING NDEA IMPURITIES THAT PROMPTED SANDOZ TO RECALL A BATCH OF ITS LOSARTAN POTASSIUM HYDROCHLOROTHIAZIDE TABLETS

09 Nov 2018

EU places China's Zhejiang Huahai under increased supervision

European authorities are placing Zhejiang Huahai Pharmaceutical Co Ltd under higher supervision, the European Medicines Agency said on Monday, in the latest crackdown on the Chinese firm after a probable carcinogen was found in its blood pressure drug valsartan.

15 Oct 2018

UPDATE 1-EU places China's Zhejiang Huahai under increased supervision

Oct 15 European authorities are placing Zhejiang Huahai Pharmaceutical Co Ltd under higher supervision, the European Medicines Agency said on Monday, in the latest crackdown on the Chinese firm after a probable carcinogen was found in its blood pressure drug valsartan.

15 Oct 2018

EU places China's Zheijiang Huahai under increased supervision

Oct 15 European authorities are placing Zhejiang Huahai Pharmaceutical Co Ltd under higher supervision, the European Medicines Agency said on Monday, after an inspection revealed lapses in quality management at the drugmaker's factory in China.

15 Oct 2018

Embattled Chinese drug maker to get $43 mln in government support

SHANGHAI, Oct 14 A Chinese city government has given 300 million yuan ($43 million) to drug maker Zhejiang Huahai Pharmaceuticals, the company said, after it was recently faulted by U.S. and European regulators over production issues at one of its plants.

14 Oct 2018

CORRECTED-(OFFICIAL)-UPDATE 3-FDA halts imports from China's Huahai Chuannan plant

SHANGHAI/NEW YORK, Sept 28 The U.S. Food and Drug Administration said on Friday it will no longer allow imports of drug ingredients or medicines made with ingredients produced at China's Zhejiang Huahai Pharmaceuticals Chuannan factory, after a recall of one of its drugs that contained a probable carcinogen.

10 Oct 2018

Chinese drugmaker Huahai tumbles after FDA shutout

SHANGHAI Shares of China's Zhejiang Huahai Pharmaceuticals Co Ltd tumbled in early trade on Monday, the first day of trading since the U.S. Food and Drug Administration halted imports of drug ingredients or medicines made by the company.

08 Oct 2018

Global health regulators find second toxin in common heart drug

(This version of the September 14th story changes final paragraph to show representative did not immediately respond to a request for comment)

17 Sep 2018

Global health regulators find second toxin in common heart drug

(This story has been refiled to change final paragraph to show representative did not immediately respond to a request for comment.)

17 Sep 2018

REFILE-UPDATE 3-Global health regulators find second toxin in common heart drug

FRANKFURT/BENGALURU, Sept 14 European and North American regulators have found a second toxin that may cause cancer in humans in a commonly used blood pressure drug made by Chinese firm Zhejiang Huahai Pharmaceutical Co Ltd.

17 Sep 2018

Earnings vs. Estimates